International
The Morning Science

What science found today

‹
 

Business

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

BioPharma Dive · By Jonathan Gardner ·

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The Brief

  • The FDA rejected ivonescimab, a PD-1/VEGF drug from Summit and Akeso, for a form of lung cancer.
  • The FDA refused to overlook the drug's failure to initially extend survival in that lung cancer population.
  • Summit shares fell, and the decision sets back Summit's first chance to win a U.S. approval.

Why it matters

The rejection shows that the FDA will not overlook a failure to show an initial survival benefit, even for a closely watched new class of cancer drug, which matters for how science readers judge the strength of trial evidence in oncology.

Who’s affected

  • investors and analysts following Summit Therapeutics
  • patients and clinicians interested in EGFR-mutated lung cancer treatments

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

Timeline

  1. FDA rejects ivonescimab for a form of lung cancer, and Summit shares fall

  2. BioPharma Dive - Latest News

    Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

How do you feel about this?

0 Comments

    Summit shares fall as FDA rejects closely watched PD-1/VEGF drug – The Morning Science